论文部分内容阅读
目的观察吉西他滨联合顺铂、地塞米松组成的GDP方案治疗复发或难治性非霍奇金淋巴瘤(NHL)疗效及不良反应。方法对21例复发或难治性NHL患者予GDP方案化疗,2周期评定效果。结果 21例中完全缓解6例(28.5%),部分缓解8例(38%),有效率66.6%,疾病进展时间7.2个月,不良反应主要为骨髓抑制。结论 GDP治疗复发或难治性NHL是安全、有效的化疗方案。
Objective To observe the efficacy and adverse reactions of gemcitabine combined with cisplatin and dexamethasone in the GDP regimen in the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL). Methods Twenty-one patients with relapsed or refractory NHL were treated with GDP regimen and evaluated by 2 cycles. Results In 21 cases, complete remission was achieved in 6 cases (28.5%), partial remission in 8 cases (38%), effective rate was 66.6% and disease progression time was 7.2 months. Adverse reactions were mainly bone marrow suppression. Conclusion GDP treatment of relapsed or refractory NHL is a safe and effective chemotherapy regimen.